Volume 28 Issue 9, September 2021
Cover Credit:A multiple myeloma cancer cell interacting with a SLAMF7-specific CAR-T cell. The remarkable clinical benefit achieved using CAR T cells to defeat B cells malignancies has prompted the use of these “living drugs” to target other types of cancer. Virus-free methods, such as transposons, can be used to equip T cells with cancer-specific CAR molecules thus potentially simplifying manufacturing and reducing toxicity. Theimageshows the interaction between a SLAMF7-specific CAR T cell (orange), generated using the Sleeping Beauty transposon technology, and a multiple myeloma target cell (green).See paper by Prommersberger et al. in this issue of Gene Therapy.
Editorial
-
Advertisement
